AZ has previously said that the LAURA results, combined with the ADAURA study of Tagrisso as adjuvant treatment of EGFR-positive NSCLC, show that EGFR inhibitors can have a dramatic impact in ...

Developed as a treatment for patients whose cancers develop a single amino acid mutation that blocks the action of AZ’s older EGFR drug, Iressa, the FLAURA trial investigated whether Tagrisso ...

Tagrisso was AZ’s second best-selling drug in 2023, generating revenue of $5.8 billion. AstraZeneca touts 'overwhelming' Tagrisso win among 3 lung cancer portfolio advancements Tagrisso is not ...

Targeting AZ's Tagrisso, Johnson & Johnson's Rybrevant combo wins key FDA nod in first-line lung cancer To hear Wildgust tell it, reaching statistical significance is only a matter of time ...

Results showed treatment with osimertinib reduced the risk of disease progression or death by 84% compared with placebo. The Food and Drug Administration (FDA) has approved Tagrisso ...

Puma Biotechnology (NASDAQ:PBYI) quickly fell 13% after a court ruled that some patents are invalid in a longstanding patent ...

Commissions do not affect our editors' opinions or evaluations. As one of the sunniest states in the country, Arizona is a prime location for homeowners to harness the power of solar energy for ...

(RTTNews) - British drug major AstraZeneca PLC (AZN, AZN.L) announced Thursday that its Tagrisso (osimertinib) has been approved in the US for the treatment of adult patients with unresectable ...